Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant.
Antoine HerbautFranck FajnkuchenLise Qu-KnafoSylvia Nghiem-BuffetBahram BodaghiAudrey Giocanti-AuréganPublished in: Journal of ophthalmology (2017)
Switching to aflibercept in refractory DME results in significant functional and anatomical improvement. The study was approved by the France Macula Federation ethical committee (FMF 2017-138).